Merck Expands Singapore Lab with Advanced Biosafety Testing Services
Merck, a leading science and technology company, has expanded its Singapore lab to provide advanced biosafety testing services for biopharma customers in the Asia Pacific region.
The expansion adds cell line characterization and GMP next-generation sequencing (NGS) capabilities to the BioReliance lab, making it the first facility in Asia-Pacific to offer both services.
The enhanced testing capabilities are designed to deliver speed, sensitivity, and sustainability for biopharma customers, supporting the industry's shift towards molecular methods and animal-free testing.
Merck's Singapore laboratory will utilize advanced molecular methods, including Blazar, a proprietary platform for rapid virus detection.
The expansion is part of Merck's broader strategy to support the region's dynamic life science ecosystem and drive scientific progress.